C1orf85 ELISA kit
- Known as:
- C1orf85 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-C1orf85-Mu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- C1orf85 ELISA kit
Related genes to: C1orf85 ELISA kit
- Gene:
- GLMP NIH gene
- Name:
- glycosylated lysosomal membrane protein
- Previous symbol:
- C1orf85
- Synonyms:
- MGC31963, NCU-G1
- Chromosome:
- 1q22
- Locus Type:
- gene with protein product
- Date approved:
- 2005-05-27
- Date modifiied:
- 2015-01-09
Related products to: C1orf85 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: C1orf85 ELISA kit
- Knee osteoarthritis (OA) is a prevalent degenerative joint disease associated with pain, functional limitation, and reduced quality of life. Although nonsteroidal anti-inflammatory drugs are widely prescribed, long-term use is limited by safety concerns. Green-lipped mussel powder (GLMP) has demonstrated anti-inflammatory and chondroprotective effects in preclinical studies. This trial evaluated the efficacy and safety of GLMP supplementation in adults with knee OA. - Source: PubMed
Publication date: 2026/07/16
Kim Hyun-TaeShin Bong-JinLee Yeon-WooPark Hye-JinPark Sun-YoungHwang Eui-HyoungHwang Man-SukLee Dong-JunShin Byung-CheulHeo In - Low-grade glioma (LGG) is a highly heterogeneous tumor, and this study aims to develop a metabolism-based classifier to identify patients with distinct prognostic risks and treatment responses for precision therapy. We utilized gene expression profiles, mutation, and clinical data from the TCGA-LGG cohort. Unsupervised clustering was applied to identify metabolism subtypes, and differences in clinical features, survival, and drug sensitivity were analyzed. Four key feature genes—SNAP91, TAGLN2, GLMP, and MCUB—were identified through machine learning, and an artificial neural network (ANN) classifier was constructed to accurately classify LGG patients into two metabolism subtypes. The results revealed significant differences in gene expression profiles and mutational landscapes between the subtypes. The metabolism subtype is a clinically independent prognostic predictor of LGG, subtype C2 has a poorer prognosis. Drug sensitivity analysis showed that subtype C2 had lower 50% inhibitory concentration(IC50) and area under curve(AUC) values for TMZ. Subsequent experimental validation revealed that high expression of TAGLN2 drove tumor progression by reprogramming cellular metabolism, including enhancing oxidative phosphorylation and activating the PI3K/Akt signaling pathway in LGG cells. Our findings highlight the potential of metabolism subtyping as a tool for precision treatment strategies in LGG. - Source: PubMed
Publication date: 2026/04/21
Tan YiqiZeng LeZhang GanghuaFang JianingYin ZhijingDeng WenzhiCao KeJiang Jiaode - Glucosamine (GlcN) is an essential amino monosaccharide widely used in pharmaceuticals, nutraceuticals, and cosmetics. Microbial fermentation presents a sustainable alternative to its traditional chemical production. However, in , competitive carbon flux towards ethanol significantly limits GlcN yields. In this study, an strain for GlcN biosynthesis was engineered by integrating heterologous (glucosamine-6-phosphate deaminase) and (glucosamine-6-phosphate phosphatase) genes. To redirect carbon flux, the pyruvate decarboxylase genes , 5, and were sequentially knocked out using the Clustered Regularly Interspaced Short Palindromic Repeats Cas9 (CRISPR-Cas9) approach, generating strains , , and . achieved a GlcN titer of 2.20 ± 0.11 g/L, a 1.54-fold increase over the parental strain, while its ethanol yield decreased by 26%. This enhancement was achieved without significantly affecting cell growth or glucose consumption. Comparative transcriptomics between the triple-knockout and parental yeasts revealed 892 differentially expressed genes. Pathways related to glycolysis and ethanol formation were predominantly downregulated, whereas pathways potentially supporting GlcN synthesis were upregulated. The engineered strain demonstrated high genetic stability over 50 generations. Our findings demonstrate that disrupting ethanol formation is an effective strategy to enhance GlcN production in , providing valuable insights for carbon flux redistribution. - Source: PubMed
Publication date: 2026/03/30
Ke MingsiZheng XinyueFeng JiaqiCheng JieshunYang Peizhou - Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) restricts the long-term efficacy of treatment in patients with lung cancer. Here, we report that the EGFR-TKI resistance mechanism is mediated by lysosome-related regulation. The overexpression of glycosylated lysosomal membrane protein (GLMP), a lysosomal membrane protein, promotes resistance to Osimertinib both in vitro and in vivo. Mechanistically, GLMP could regulate the ubiquitination of RhoA and promote resistance by activating the epithelial-mesenchymal transition (EMT), which involves the RhoA pathway and activates the late stage of autophagy. Inhibition of the RhoA pathway alone enhances the initiation stage of autophagy. Lysosomal hyperactivity in TKI-resistant cells sustains the flow of autophagy. Therefore, the combined inhibition of the RhoA pathway and autophagy can effectively attenuate EGFR-TKI resistance. Our findings provide a potential therapeutic strategy to overcome resistance to EGFR-TKIs. - Source: PubMed
Publication date: 2025/11/26
Liang XiaoXu JialiShu SuhuiLv WeiYin DandanMiao SunanLu XiyiZhang ChenLiu XinyinDai JialiLi JunWu WeibingZhang ErbaoGuo Renhua - Glucosamine (GlcN) is a high-value compound with significant health applications. GlcN is widely used in the food and health industry as a food additive or functional food. The development of a green, efficient, and safe method for GlcN production is of great significance due to the complexity of traditional production methods, environmental pollution, and sensitization of raw materials. In this study, genes , , , , and were knocked out using the Clustered Regularly Interspaced Short Palindromic Repeats Cas9 (CRISPR-Cas9) method. In addition, three key enzyme genes, glucosamine-6-phosphate deaminase , glucosamine-6-phosphate phosphatase , and ammonium transporter , were introduced to construct engineered strains for GlcN synthesis in the presence of high-concentration inorganic ammonium ions. The results indicated that HPG5 with , , and integration and simultaneous deletion of , , , , and achieved the highest GlcN yield (1.95 ± 0.02 g/L) during fermentation with 10 g/L (NH)SO, which was 2.47-fold higher than the control. The conversion rate of glucose to GlcN in HPG5 was 9.75% in liquid YPD medium containing 20 g/L of glucose and 10 g/L of (NH)SO. Thus, the results indicated that HPG5 could effectively produce GlcN in the presence of high-concentration ammonium sulphate. This study provides a promising alternative, HPG5, for GlcN production. - Source: PubMed
Publication date: 2025/08/10
Yang PeizhouKe MingsiFeng JiaqiZheng ZhiJiang Shaotong